Osborne Clarke Amsterdam represented INKEF Capital, Gilde Healthcare, Thuja Capital Healthcare, Health Innovation Fund, Van Herk Ventures (sellers) in the sale of NightBalance to Royal Philips. Nightbalance is a digital health scale-up company based in the Netherlands, that has developed an innovative, easy to use device to treat positional obstructive sleep apnea and positional snoring.
Osborne Clarke Amsterdam represented new investors INKEF Capital and Sectoral Asset Management as well as existing investors Sofinnova Ventures and Ysios Capital in respect of the USD 50 million Series B financing round of BioClin Therapeutics. Other investors include HealthCap, Tekla Capital Management funds and Life Sciences Partners (LSP).
Advised HH Global, an award winning leading independent marketing execution partner to global brands in over 40 countries employing over 850 employees, with its acquisition of PostNL Print Management, the print management arm of the Dutch postal and logistic solutions provider PostNL, to help support HH Global’s growth in the Netherlands.
Represented Gilde Healthcare and key management (sellers) in the auction sale of ViroClinics Biosciences B.V. to Parcom Capital, a leading mid-market private equity firm in the Benelux, as well key management in their continuing investment in ViroClinics post-closing.
Advised A-Gas on the acquisition of Netherlands’ reclamation business BTC.
Represented Terumo Corporation in respect of the staged transaction with Quirem Medical, in which Terumo Corporation following its initial minority interest (i) increased its minority interest, (ii) acquired the exclusive worldwide distribution rights and (iii) obtained a purchase option to acquire the remaining of the shares.
Represented Breath Therapeutics on EUR 43.5m Series A financing round by Gimv, Sofinnova Partners and Gilde Healthcare.
Show 4 more
Sofinnova Ventures & Ysios Capital
Represented Sofinnova Ventures and Ysios Capital as lead investors in the USD 30 million Series B Financing round of BioClin Therapeutics.